Keenova Therapeutics Director Paul Bisaro Receives RSU Award

What Happened Paul Bisaro, a director of Keenova Therapeutics plc, received an award of 4,406 restricted stock units (RSUs) on July 15, 2026. The RSUs are reported at $0.00 per unit (no cash paid) and are classified as a derivative award; no immediate cash value is listed in the Form 4.

Key Details

• Transaction date: 2026-07-15; Form 4 filed 2026-07-17.
• Transaction type/code: A (Grant/Award) — 4,406 RSUs @ $0.00 (derivative).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes: F1 — each RSU will be settled 1-for-1 into ordinary shares upon vesting. F2 — RSUs vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the issuer’s next annual general meeting.
• Filing timeliness: Form 4 was filed two days after the transaction date, within the typical 2-business-day reporting window for insiders.
• Remarks: The filing also serves as notice to the issuer under Part V of the Companies Act 2014.

Context RSU grants are a common form of executive/director compensation and do not represent an open‑market purchase or sale. These RSUs are a conditional entitlement to ordinary shares in the future (one share per RSU) if and when the vesting conditions are met; they do not by themselves signal immediate buying or selling of stock.